Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Biol Psychiatry. 2012 Jul 27;74(4):250–256. doi: 10.1016/j.biopsych.2012.06.022

Figure 3. Risk of Relapse Among Responders to Repeated Ketamine Infusions in Treatment-Resistant Major Depression.

Figure 3

Figure depicts survival analysis conducted in 17 phase I responders following six infusions of ketamine (maximum follow up time = 83 days). Relapse in phase II was defined as <50% improvement in MADRS score at that visit compared to baseline for two consecutive visits. The number at risk at each time point is indicated along the bottom of the graph.